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Abstract
Objective—We aimed to investigate the effects of special packaging (child-resistant, adult-
friendly) and tamper-resistant packaging on health and behavioral outcomes in order to identify 
research gaps and implications for packaging standards for tobacco products.
Methods—We searched seven databases for keywords related to special and tamper-resistant 
packaging, consulted experts, and reviewed citations of potentially relevant studies. 733 unique 
papers were identified. Two coders independently screened each title and abstract for eligibility. 
They then reviewed the full text of the remaining papers for a second round of eligibility 
screening. Included studies investigated a causal relationship between type of packaging or 
packaging regulation and behavioral or health outcomes and had a study population composed of 
consumers. Studies were excluded on the basis of publication type, if they were not peer-reviewed, 
and if they had low external validity. Two reviewers independently coded each paper for study and 
methodological characteristics and limitations. Discrepancies were discussed and resolved.
Results—The review included eight studies: four assessing people’s ability to access the contents 
of different packaging types and four evaluating the impact of packaging requirements on health-
related outcomes. Child-resistant packaging was generally more difficult to open than non-child-
resistant packaging. Child-resistant packaging requirements have been associated with reductions 
in child mortality.
Conclusions—Child-resistant packaging holds the expectation to reduce tobacco product 
poisonings among children under six.
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1. Introduction
Every year in the United States there are an average of 50,000 cases of unintentional 
poisonings among children under age six years (Centers for Disease Control and Prevention, 
2013), and a significant proportion of these poisonings are related to tobacco products. From 
2006 through 2008, the National Poison Data System reported 13,705 cases of tobacco 
product ingestion by children under six (Connolly et al., 2010). During these years, ingested 
tobacco products included cigarettes, smokeless tobacco (chewing tobacco and snuff), and 
cigars (Connolly et al., 2010).
The marketplace of tobacco products is ever changing, and novel tobacco products such as 
dissolvables, snus, and electronic cigarettes (e-cigarettes or ENDS – electronic nicotine 
delivery devices) have raised new concerns about poisoning, given their potential appeal to 
children.
Some dissolvable products, like Camel Orbs®, have a candy-like appearance and come in 
flavors like mint and cinnamon (Wilson, 2010). Snus, another oral tobacco product, is 
available in flavors like “frost” and “winterchill” (TobaccoProducts.Org, 2010). Snus is a 
traditional Swedish smokeless tobacco product made from moist, finely ground tobacco and 
sold in small sachets or in loose form (National Cancer Institute, 2014). E-liquids, or the 
liquids used in e-cigarette devices, are offered in fruit and sweet flavors (e.g., strawberry 
banana smoothie, pink lemonade, caramel apple fritter) (Popular E-Liquid, 2016). These 
tobacco products have all been linked to poisonings in children (Connolly et al., 2010; 
Forrester, 2015; Vakkalanka et al., 2014).
E-liquids and other e-cigarette components have received particular attention, given the 
growing popularity of e-cigarettes (Arrazola et al., 2015; Pepper and Brewer, 2014), the 
April 2015 U.S. death of a toddler due to e-liquid ingestion (Clukey, 2015), and the rapid 
increase in poisoning cases due to e-cigarette exposure (Forrester, 2015; Vakkalanka et al., 
2014; Chatham-Stephens et al., 2014). Chatham-Stephens et al. (2014) analyzed e-cigarette 
and cigarette-related calls made to U.S. poison centers from 2010 to 2014. E-cigarette 
exposures represented a growing proportion of these calls, from 0.3% in September 2010 to 
about 42% in 2014. Most e-cigarette exposures have been reported as ingestions (Forrester, 
2015; Durmowicz, 2014) and for children under six years (Vakkalanka et al., 2014; 
Chatham-Stephens et al., 2014; Ordonez et al., 2015). Negative health effects associated 
with e-cigarette exposure have included vomiting, nausea, eye irritation, headaches, and 
dizziness (Chatham-Stephens et al., 2014; Ordonez et al., 2015). The U.S. Food and Drug 
Administration’s adverse event database, which includes consumers’ complaints associated 
with e-cigarettes, has also reported the death of an infant due to choking on an e-cigarette 
cartridge (Durmowicz, 2014).
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In response to this public health threat, some manufacturers of e-cigarettes, dissolvables, and 
snus have voluntarily packaged their products in child-resistant containers (Wilson, 2010; 
Buettner-Schmidt et al., 2016; Nikitin et al., 2016; Rosetta, 2009). E-cigarette liquids have 
been reported to include press-and-turn closures resembling those used for aspirin (Buettner-
Schmidt et al., 2016; Nikitin et al., 2016). At least one tobacco product manufacturer has 
claimed that its dissolvable packaging is child-resistant (Connolly et al., 2010). In general 
though, e-liquids have been sold in containers that are not considered child-resistant 
(Chatham-Stephens et al., 2016; Kamboj et al., 2016).
Policymakers at the local, state, federal, and global levels have also begun implementing 
legislation requiring child-resistant packaging for liquids and occasionally gels, cartridges, 
or other e-cigarette paraphernalia (114th Congress, 2015; Frey and Tilburg, 2016; Bear River 
Board of Health, 2014; European Parliament and the Council of the European Union, 2014). 
In July 2015 the U.S. Food and Drug Administration issued an Advance Notice of Proposed 
Rulemaking soliciting information to guide regulatory development around child-resistant 
packaging for nicotine liquid and other tobacco products (e.g., gels, dissolvables) (U.S. 
Department of Health and Human Services, 2015). In January 2016 special packaging 
standards, which had been in place for household substances, were expanded to include 
liquid nicotine through the Child Nicotine Poisoning Prevention Act (114th Congress, 
2015). Special packaging is defined as packaging that is “significantly difficult for children 
under 5 years of age to open or obtain a toxic or harmful amount of the substance contained 
therein within a reasonable time and not difficult for normal adults to use properly” (Code of 
Federal Regulations, 1973).
Another dimension of packaging distinct from special packaging but potentially relevant to 
packaging standards for tobacco products is resistance to tampering. Tamper-resistant 
packaging, which is required for over-the-counter drugs, aims to prevent the post-
manufacture altering of products and to enable consumers to determine easily whether or not 
their product may have been altered (e.g., seal is missing from medication container) (Code 
of Federal Regulations, 2016). In contrast to special packaging, tamper-resistant packaging, 
to our knowledge, has not been mentioned in news stories or policies related to tobacco 
products. However, given the poor quality control exhibited by some e-cigarette 
manufacturers (Cobb et al., 2010; Lisko et al., 2015), policymakers may want to consider 
including tamper-resistant design features as one way to address quality control in 
packaging.
To help inform ongoing and future legislative and regulatory efforts, we conducted a 
systematic review to investigate the effects of special and tamper-resistant packaging on the 
health and behavioral outcomes of individuals. We aimed to identify research gaps and 
implications for packaging standards for tobacco products. For the purpose of this review, 
we use the terms “child-resistant” and “special packaging” interchangeably.
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2. Methods
2.1. Search strategy
We developed two search strings, one containing keywords related to special packaging and 
one containing words related to tamper-resistant packaging. Through an iterative process, we 
analyzed the results generated by each string and added to and refined the strings to capture 
relevant articles and to reduce the number of irrelevant articles. We used and adapted, as 
necessary, the search strings to search for literature in seven databases: Academic Search 
Complete, Business Source Complete, CINAHL Plus with Full Text, Embase, PubMed, 
SciFinder, and Web of Science. The search strings for each database and the overall review 
protocol are available from the corresponding author. An example of a final PubMed search 
string is ((Child-resistant[TIAB] OR “child resistant”[TIAB] OR child-proof[TIAB] OR 
childproof[TIAB] OR “child proof”[TIAB] OR “safety packaging”[TIAB] OR “special 
packaging”[TIAB] OR “safety caps”[TIAB] OR “safety cap”[TIAB]) AND (“Poisoning/
prevention and control”[MH] OR “drug packaging”[TIAB] OR “packaging materials”
[TIAB] OR “abuse deterrent”[TIAB] OR “abuse liability”[TIAB] OR abuse-
deterrent[TIAB] OR “Drug Packaging”[MH] OR “Consumer Product Safety”[MH] OR 
“consumer product safety”[TIAB] OR “Product Packaging”[MH] OR “product packaging”
[TIAB] OR “Poison Prevention Packaging Act”[TIAB] OR “Food Packaging”[MH] OR 
“food packaging”[TIAB] OR “blister pack”[TIAB] OR “blister packs”[TIAB])). Our 
searches included all studies, regardless of date published, geography, and language. 
Searches were conducted between July 8, 2014 and July 18, 2014.
Our database searches resulted in 944 records (see Fig. 1). We identified an additional 46 
records by contacting experts in packaging and by reviewing the citations of 10 potentially-
relevant articles. Records were imported into reference managing software.
2.2. Eligibility criteria
Included studies investigated a causal relationship between type of packaging or packaging 
regulation (a measured or manipulated variable) and a behavioral or health outcome. Note 
that this criterion, by definition, excluded descriptive studies. Included studies also had a 
study population of consumers as opposed to a non-consumer population, like health care 
professionals. Non-English studies were included and translated in-house.
Non-peer-reviewed articles were excluded, as were conference abstracts, case studies, and 
articles for which full text was not available. We excluded review articles since we assumed 
our search strings would have captured any relevant studies that reviews would have 
reported. We excluded studies if they had low external validity or lacked data to assess 
external validity (e.g., country of data collection not reported). Studies were marked as 
having low external validity if they (1) took place in a country outside of the United States 
and provided minimal detail about the packaging being tested or regulation being 
implemented or (2) included only data collected before 1985. Results from studies meeting 
these criteria were challenging to interpret for the U.S. context, given the wide variety of 
child-resistant packaging available globally and the major developments in packaging over 
the past 30 years.
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2.3. Eligibility coding
After de-duplicating the records, the first and second authors independently screened the 733 
papers for eligibility in two phases. In the first phase, they reviewed titles and abstracts 
independently and resolved all coding discrepancies through discussion. If agreement could 
not be reached, they consulted the third and last authors.
After this phase of screening, 132 papers remained as potentially meeting eligibility criteria. 
These records included those for which eligibility could not be determined from the title and 
abstract alone (e.g., abstract was missing or vague). The first and second authors 
independently reviewed the full text of these articles for eligibility, discussed and resolved 
coding discrepancies, and consulted the third and last authors, as necessary. One hundred 
twenty-four records were excluded during this phase, leaving eight studies for inclusion in 
qualitative synthesis.
2.4. Data abstraction
The first and second authors independently coded the articles for study and methodological 
characteristics, using a data abstraction form. Discrepancies were discussed and resolved. 
Study characteristics included the study population, country in which the study took place, 
data collection dates, types of products involved (e.g., oblong tablets, mouthwash), and 
financial disclosures (i.e., industry, government, not reported). Methodological 
characteristics included the study design and the independent and dependent variables. 
Independent variables fell into two categories: (1) packaging design features or (2) the 
implementation of packaging rules or requirements. For studies investigating packaging 
design features, we captured details about the packaging tested, including the type of 
opening and size of the packaging or container, if available. For studies involving packaging 
rules or requirements, we noted when the policy came into place. Dependent variables 
represented dimensions of functional ability (e.g., ability to empty a package or not, time 
required to open) and health outcomes resulting from poisoning ingestions. We reported the 
direction of results and results of sub-group analyses conducted, if any. We further coded for 
whether or not randomization took place or an a priori power analysis was conducted.
Based on a scan of quality assessment tools and resources (Deeks et al., 2003; Institute of 
Medicine, 2011; Committee to Review the IRIS Process, 2014; Sanderson et al., 2007; 
National Toxicology Program Office of Health Assessment and Translation, 2015; Turner et 
al., 2013; West et al., 2002; Whiting et al., 2004; Zaza et al., 2000), we identified four 
categories of study limitations that we considered to be relevant to the included studies and 
feasible to assess: limitations with regard to study description, sampling, measurement, and 
interpretation of results. Study description limitations included the lack of a clear research 
question and lack of details regarding where and when the study took place and who 
participated in the study (i.e., age, sex). For structured observational studies, we additionally 
tracked if the study lacked detail on the study procedure (e.g., what behaviors were being 
observed). We coded for sampling limitations if the sampling frame or screening criteria for 
study eligibility were not reported, if a non-probability sample was taken, and if the 
participation rate was under 80%.
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Measurement limitations primarily focused on reliability and validity. Reliability issues 
included failure to mention procedures to estimate some form of reliability, such as internal 
consistency or test-retest reliability. If reported, we looked for reliability coefficients of at 
least 0.70 (Kline, 2011). We also noted if authors qualitatively described any reliability 
issues. For validity, we tracked when the definitions of the independent or dependent 
variables were unclear. For example, if packaging type was the independent variable, we 
sought a description of the size and opening mechanism of the packages. We coded the lack 
of such descriptions as limitations. Other validity issues were the failures to use multiple 
measures to assess the outcome and to provide evidence of construct validity (e.g., 
demonstration of convergent or discriminant validity) of measured variables. For studies 
involving an intervention, like the implementation of packaging rules or requirements, we 
additionally considered lack of a controlled exposure to the intervention to be a 
measurement limitation.
The next category of limitations related to the interpretation of results. These limitations 
included the failure to discuss potential confounders. If discussed, we noted attempts to 
control for and potential biases resulting from these confounders (e.g., instrumentation bias 
resulting from a change in a measure used in a study). Another limitation was reporting high 
attrition (i.e., over 20%) without explaining why attrition occurred or how it could have 
affected the results. When non-randomized studies included control or comparison groups, 
we assessed if the groups were appropriate (i.e., groups were similar on age, sex, or other 
demographic characteristics). Studies with inappropriate groups were coded as having a 
limitation since selection bias could have occurred. For structured observational studies, we 
noted if the stimuli were presented to participants in random, varying (non-random), or fixed 
order. Presenting stimuli in a fixed order was considered to be a limitation since it could 
result in order effects. Lastly, we reviewed characteristics of the study samples. For example, 
a sample being disproportionately composed of a certain demographic could affect the 
interpretation of results. We opted not to provide a quality score given the variability in 
design and outcomes across the studies and the limited value of assigning weights to 
disparate dimensions of quality. Instead, we report the limitations identified for each study 
and summarize key findings.
3. Results
The eight studies included in this review were published from 1988 to 2013. All but one 
study took place in the United States (Keram and Williams, 1988; Lovegrove et al., 2013; 
Massey and Shulman, 2006; Meyer and Schuna, 1989; Mrvos and Krenzelok, 2007; 
Rodgers, 1996; Rodgers, 2002). The non-US study took place in Germany (Muhlfeld et al., 
2012). Four studies involved structured observations, where researchers assessed 
participants’ ability to open different types of packaging, using a test protocol (Keram and 
Williams, 1988; Lovegrove et al., 2013; Meyer and Schuna, 1989; Muhlfeld et al., 2012). 
The remaining four studies had an interrupted time series design, where the interruption was 
a policy or regulation related to special packaging (Massey and Shulman, 2006; Mrvos and 
Krenzelok, 2007; Rodgers, 1996; Rodgers, 2002). Three structured observational studies 
involved persons over the age of sixty (Keram and Williams, 1988; Meyer and Schuna, 
1989; Muhlfeld et al., 2012), while one structured observational study involved children 
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under the age of six (Lovegrove et al., 2013). All four interrupted time series studies 
involved children under six (Massey and Shulman, 2006; Mrvos and Krenzelok, 2007; 
Rodgers, 1996; Rodgers, 2002). Sample size ranged from 50 to 141 participants for the 
structured observational studies and 10 to 29 time points for the interrupted time series 
studies. One study involved randomization (Lovegrove et al., 2013). This same study was the 
only study to report conducting an a priori power analysis (Lovegrove et al., 2013). Of the 
studies reporting their funding source (k = 4), two reported receiving industry funding (i.e., 
funding from and/or equipment and materials provided by a private company). One reported 
government funding, and one reported government funding and funding from an undisclosed 
source. See Supplementary Table 1 for study characteristics.
Several limitations were either identified in the manuscripts or through the review. Two 
studies failed to report when the study was conducted (Keram and Williams, 1988; Meyer 
and Schuna, 1989). Seven studies used non-probability sampling (Keram and Williams, 
1988; Lovegrove et al., 2013; Massey and Shulman, 2006; Mrvos and Krenzelok, 2007; 
Rodgers, 1996; Rodgers, 2002; Muhlfeld et al., 2012), which limits our ability to draw 
conclusions about their respective target populations: children (Lovegrove et al., 2013) and 
the elderly for the structured observational studies and time periods for the interrupted time 
series studies (Keram and Williams, 1988; Mrvos and Krenzelok, 2007; Muhlfeld et al., 
2012). One study failed to report study eligibility criteria (Muhlfeld et al., 2012).
None of the studies discussed issues related to reliability, provided reliability estimates, or 
provided evidence of construct validity (Keram and Williams, 1988; Lovegrove et al., 2013; 
Massey and Shulman, 2006; Meyer and Schuna, 1989; Mrvos and Krenzelok, 2007; 
Rodgers, 1996; Rodgers, 2002; Muhlfeld et al., 2012). Other validity limitations included 
the lack of clear definitions of the type of packaging assessed (Keram and Williams, 1988) 
and the failure to use more than one measure to assess the dependent variable (Massey and 
Shulman, 2006; Meyer and Schuna, 1989; Mrvos and Krenzelok, 2007). The four 
interrupted time series studies assessed the impact of an intervention, that is, packaging rules 
or requirements, on health or behavioral outcomes. These studies had the additional validity 
limitation of failing to control exposure to the intervention, although this is to be expected, 
given that the interventions were environmental variables (Massey and Shulman, 2006; 
Mrvos and Krenzelok, 2007; Rodgers, 1996; Rodgers, 2002).
Regarding the interpretation of results, a key limitation among structured observational 
studies was the failure to mention the order in which stimuli were presented to participants 
(Keram and Williams, 1988; Meyer and Schuna, 1989). Another limitation was the 
composition of study samples. Three structured observational studies had disproportionate 
numbers of males to females in the samples (Keram and Williams, 1988; Meyer and Schuna, 
1989; Muhlfeld et al., 2012).
Interrupted time series studies generally reported and, in differing degrees, discussed or 
attempted to control for the impact of potential sources of bias. Common sources of bias 
included instrumentation (Mrvos and Krenzelok, 2007; Rodgers, 1996; Rodgers, 2002), 
history (e.g., change in number of poison reporting centers) (Mrvos and Krenzelok, 2007; 
Rodgers, 1996; Rodgers, 2002), and maturation (e.g., increase in reporting of 
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overingestions) (Massey and Shulman, 2006; Mrvos and Krenzelok, 2007; Rodgers, 1996; 
Rodgers, 2002; Done et al., 1971). Another common limitation was the failure to report 
whether pre- and post-intervention groups were well-matched with regard to demographic 
characteristics, which could suggest selection bias (Massey and Shulman, 2006; Rodgers, 
1996; Rodgers, 2002).
3.1. Structured observational studies
Studies assessed packaging for medications in tablet (k = 3) (Keram and Williams, 1988; 
Meyer and Schuna, 1989; Muhlfeld et al., 2012), liquid (k = 2) (Keram and Williams, 1988; 
Lovegrove et al., 2013), and/or patch form (k = 1) (Keram and Williams, 1988). See 
Supplementary Table 2 for detailed descriptions of the designs tested and study results. 
Muhlfeld et al. (2012) compared five different types of blister designs on the usability and 
preferences of older adults. The one child-resistant design tested required the participant to 
peel-off the polyethylene terephthalate layer of the foil covering the blister and to push 
through the remaining aluminum foil layer (Muhlfeld et al., 2012). The other designs 
required the participant to peel off or push through the lidding foil. Study authors measured 
five outcomes: level of difficulty associated with opening the blister, participants’ overall 
assessment of the package (i.e., good, intermediate, bad), whether or not participants 
experienced pain when opening, whether or not participants gave up trying to open the 
package, and the number of tablets removed. Of all designs, the child-resistant design was 
found to be the least accessible and the most negatively assessed. More participants rated it 
as being “very difficult” to open than any other design, and it received the highest number of 
negative overall ratings (Muhlfeld et al., 2012). Pain was reported by the highest proportion 
of participants trying to open the child-resistant design (Muhlfeld et al., 2012). Relative to 
all other designs tested, a higher proportion of participants gave up when trying to open the 
child-resistant design and failed to remove four tablets from the pack (Muhlfeld et al., 2012). 
Female participants, older participants (i.e., aged 86+), and participants with diseases like 
rheumatism, stroke, arthritis, and Parkinson’s disease or poor vision were less likely to be 
able to open and obtain the tablets in the blister than their male, younger, and non-disease 
counterparts (Muhlfeld et al., 2012).
Meyer and Schuna (1989) assessed older adults’ ability to open packaging for tablet 
medications and compared two types of containers. The first container had a child-resistant 
opening mechanism that required the participant to push down and turn the cap (Meyer and 
Schuna, 1989). The second container was a non-child-resistant “flip cap” (Meyer and 
Schuna, 1989). The researchers did not find statistically significant differences in 
participants’ ability to open the two containers (Meyer and Schuna, 1989).
Keram and Williams (1988) tested older adults’ ability to open 15 different medication 
containers, including six child-resistant designs, four non-child-resistant designs, three nitro-
glycerin patches, and two miscellaneous containers (i.e., blister pack, plastic pocket box), 
which the authors considered to be child-resistant in their analysis. Adults took longer to 
open the child-resistant designs than the non-child-resistant designs (Keram and Williams, 
1988). In addition, none of the child-resistant designs could be opened by all participants, 
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while all participants could open the non-child-resistant designs (Keram and Williams, 
1988).
Lovegrove et al. (2013) were the only researchers to use structured observation to assess the 
effect of packaging design among children. They investigated how the inclusion of flow 
restrictors on bottle openings affected children’s ability to empty bottle contents. Each 
participant attempted to empty the liquid contents of two bottles (Lovegrove et al., 2013). 
The first was an open bottle without a cap but with a flow restrictor (Lovegrove et al., 2013). 
One of three different designs of flow restrictors and accompanying bottles were used for 
this condition (Lovegrove et al., 2013). The second bottle tested served as the control and 
was either an open bottle without a cap or a bottle with an incompletely closed child-
resistant cap (Lovegrove et al., 2013). If the participant failed to empty either bottle in five 
minutes, the researchers demonstrated how to remove the liquid (Lovegrove et al., 2013). 
Regardless of whether a demonstration was provided, children were less successful at 
emptying completely and removing different amounts of test liquid from the flow restrictor 
bottle compared to the control bottles (Lovegrove et al., 2013). Older children (i.e., aged 54–
59 months) were more likely to be able to empty the flow restrictor bottles than younger 
children (Lovegrove et al., 2013).
3.2. Interrupted time series studies
Interrupted time series studies investigated the effects of policies requiring child-resistant 
packaging for ethanol-containing mouthwash in 1995 (k = 2) (Massey and Shulman, 2006; 
Mrvos and Krenzelok, 2007), aspirin-containing products in 1972 (k = 1) (Rodgers, 2002), 
and oral prescription drugs in 1974 (k = 1) (Rodgers, 1996). Mrvos and Krenzelok (2007) 
analyzed data from 1985 through 2005 on toxic exposures involving children and the 
ingestion of ethanol-containing mouthwash. The number of toxic exposures dropped during 
the year that child-resistant packaging requirements were implemented, but the total number 
of exposures post-implementation of the requirements was greater than the total number pre-
implementation (Mrvos and Krenzelok, 2007). The researchers were unable to determine 
whether this effect was a result of the increased availability of ethanol-containing 
mouthwash or the failure of child-resistant packaging requirements (Mrvos and Krenzelok, 
2007). However, they found some evidence that health outcomes related to the exposures 
were less severe after the rule was implemented (Mrvos and Krenzelok, 2007).
In another study assessing the effect of the 1995 rule, Massey and Shulman (2006) analyzed 
data on the incidence of overingestion of ethanol-containing mouthwash from 1989 through 
2003. In contrast to the previous study, the researchers adjusted the number of exposures by 
the proportion of the US population under six and served by poison control centers (Massey 
and Shulman, 2006). The incidence of overingestions involving mouthwash decreased after 
the implementation of the 1995 rule but began to increase in 2002 (Massey and Shulman, 
2006).
Rodgers assessed the impact of child-resistant packaging requirements on aspirin-containing 
products (Rodgers, 2002) and oral prescription drugs (Rodgers, 1996). In both studies, he 
used multivariate regression models to estimate the effect of the requirements on the child 
mortality rate, while taking into account potential confounding variables (Rodgers, 1996; 
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Rodgers, 2002). Both studies included a large number of time points before and after the 
intervention. The study on aspirin-containing products included data from 1958 through 
1990 (Rodgers, 2002), while the study on oral prescription drugs included data from 1964 
through 1992 (Rodgers, 1996). Both studies found statistically significant declines in child 
mortality as a result of the packaging requirements (Rodgers, 1996; Rodgers, 2002).
4. Discussion
We sought to summarize the literature on the effects of special packaging on health and 
behavioral outcomes. Studies have generally found that products with child-resistant designs 
have been more difficult to access than those with non-child-resistant designs. Moreover, 
child-resistant packaging requirements for oral prescription and aspirin-containing products 
have been associated with reductions in child mortality. Although only a small number of 
studies have been conducted and a small number of packaging designs have been assessed, it 
is reasonable to infer that child-resistant packaging has had a positive effect in reducing 
toxicant exposures in children and associated mortality. If applied to tobacco products, child-
resistant packaging would likely reduce tobacco-related ingestions.
It is worth noting that child-resistant designs were not only difficult for children to access 
but also older adults. With the Child Nicotine Poisoning Prevention Act, liquid nicotine 
containers in the U.S. will need to satisfy the child-resistant requirements and pass the “ease 
of adult opening” tests outlined in section 1700.15 of the Poison Prevention Packaging Act 
(114th Congress, 2015; Code of Federal Regulations, 1973). “Ease of adult opening” tests 
are intended to ensure that adults aged 50 to 70 can successfully access the product as 
outlined in section 1700.20 of the Poison Prevention Packaging Act (Code of Federal 
Regulations, 1973). Including such tests in child-resistant regulation could indirectly prevent 
pediatric ingestions of tobacco products. Significant proportions of pediatric poisonings have 
been linked to the ingestion of grandparents’ medications, and improper storage of 
medication has been cited as a potential factor (McFee and Caraccio, 2006; Jacobson et al., 
1989). Older adults who struggle to open child-resistant containers may leave these 
containers open or transfer the contents to non-child-resistant packages (e.g., plastic bags), 
which could increase the likelihood of pediatric poisoning. Tobacco use, including e-
cigarette use, is lower among the geriatric population than other age groups (King et al., 
2015; U.S. Department of Health and Human Services, 2014). However, policymakers 
proposing child-resistant regulations may still want to consider including “ease of adult” 
tests in addition to child-resistant tests for tobacco products.
This review has identified several areas for future research. First, research on the ability of 
children to open special packaging would be informative as they are vulnerable to 
poisonings due to tobacco product ingestion, particularly e-liquids and electronic cigarette 
cartridges. Second, from a methodological standpoint, researchers should consider 
randomizing the order of stimuli in these studies, using probability samples, assessing and 
reporting on the psychometric properties of measures, and providing detailed descriptions of 
the packaging designs being compared. Third, studies assessing packaging types as varied as 
those that house tobacco products would be useful. Research studies should also consider 
evaluating a range of tobacco product formulations. For example, Lovegrove et al. (2013) 
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tested flow restrictors and bottle designs that were being used for liquid medicines in the 
United States at the time of the study. Their results may not generalize to all flow restrictor 
or bottle types or to bottles with different contents (e.g., non-liquid or different viscosity) 
(Lovegrove et al., 2013). Fourth, as jurisdictions begin to implement child-resistant 
packaging requirements for e-cigarette liquids and components, opportunities to conduct 
natural experiments exist. In addition to analyzing data prior to and after the implementation 
of such requirements, such as the interrupted time series studies included in the review, 
researchers could consider analyzing data from a control community that has not 
implemented such requirements. Such a design would be an improvement over existing 
designs since it could help researchers assess the impact of historical factors that could be 
biasing study results. Fifth, research suggests that the size and shape of the container (Keram 
and Williams, 1988), material of the cap (Done et al., 1971), and force required to open the 
container (Page, 1981) could influence the effectiveness of special packaging. Future studies 
could manipulate these factors and evaluate their independent and combined impacts on 
participants’ opening ability. Lastly, although we aimed to investigate tamper-resistant 
packaging in addition to child-resistant packaging, we did not locate any articles on this 
topic. Tamper-resistant packaging may be a promising area of research associated with 
tobacco products.
Strengths of this study include our comprehensive search of the literature and our 
independent approach to screening articles for eligibility and coding data. Limitations are 
that we may have missed potentially informative articles as a result of our eligibility criteria. 
Since we excluded descriptive studies, studies reporting the pattern of poisoning ingestions 
over time without including packaging type or regulation as an independent variable were 
excluded. Though outside the scope of our review, descriptive studies like these and review 
articles may yield potentially useful information to policymakers. Also, as noted previously, 
a number of studies were excluded due to low external validity or insufficient data to assess 
external validity. Despite excluding them from this review, we reviewed their results post-
hoc and found them to be generally in line with our study findings.
5. Conclusion
To our knowledge, this is the first systematic review to assess the effects of special 
packaging on health and behavioral outcomes. Although more studies would expand the 
evidence base, child-resistant packaging holds the expectation to reduce tobacco product 
poisonings among children under six years. This review supports the growing number of 
efforts to require child-resistant packaging for e-cigarette products.
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Fig. 1. 
Flow diagram of literature search and article identification.
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